ORANGE COUNTY, CALIF. (January 11, 2011) - Beckman Coulter, Inc. announces the release of its 2011 Cellular Analysis eCatalog, which combines with www.coulterflow.com to provide a comprehensive, adaptable and eco-friendly resource that simplifies the reagent and instrument selection process and improves day-to-day management of a lab's experiments and needs.

This advanced interactive publication provides user-friendly search capabilities and is regularly updated with Beckman Coulter's latest product innovations in flow cytometry. Customized print-on-demand function for both clinical and research applications provides hard copy for user-specified sections.

"We've designed the eCatalog and web site to be 'virtual assistants' that help the scientist develop, plan and manage their experiments," said Brad Calvin, vice president of Beckman Coulter Flow Cytometry. "Making a virtual catalog allowed for an environmentally friendly publication that provides customers with access to the dynamic resources offered by the web."

In addition to the Cellular Analysis eCatalog, www coulterflow.com, offers scientists a range of interactive tools and custom software applications that facilitate organization and experiment design. Lab management tools include My Lab Workbench, which helps users create product lists, organize folders and add notes and references to experiments; Experiment Designer, which allows users to plot, compare and check the spectral compatibility of many fluorophores and to define and provide a written record of an experiment; and Tetramer Wizard, which facilitates the selection of Tetramers and iTopia products, as well as the creation of custom peptide sequences.

Interactive applications simplify the product selection process and include a tool for creating two-, three- or four-color conjugate configurations for use with an extensive line of human and mouse antibodies, and Spectrios, a tool that gathers data on the spectral information associated with fluorochromes that are commonly utilized in flow cytometry, allowing users to model the behavior of commonly used cytometers.

About Beckman Coulter
Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. This year marks the company's 75th anniversary of advancing healthcare. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of consumable supplies (including reagent test kits), service and operating-type lease payments, represents about 80 percent of the company's 2009 revenue of $3.3 billion. For more information, visit www.beckmancoulter.com or www.beckmancoulter.com/75years.

Visit the eCatalog on-line interactive web page.

Click here or on the icon to collapse this window

ORANGE COUNTY, Calif. (December 1, 2010) - MoFlo Astrios next-generation cell sorter from Beckman Coulter, Inc. leverages the stable fluidic design of the original MoFlo and the electronic processing of the MoFlo XDP, while expanding sorting capabilities with an array of laser options. A range of unique software components further enhances instrument functionality.

Complex, multi-color sorting is enabled by seven pinholes that spatially separate each of the seven lasers. Auto start-up allows the researcher to define when lasers and fluidics turn on, saving valuable time. The multi-fiber Beam Shaping Optic creates flat-top beam profiles, providing short alignment times and high-level optic stability. Two stages control the alignment for all seven lasers to simplify sorter preparation.

Beckman Coulter's IntelliSort II is a bead-less drop delay determination and monitoring system. Camera images and proprietary algorithms determine optimal drop delay without fluorescent beads being incorporated in the sample line. A quick-release nozzle design enables easy removal or swapping of the nozzle body and tip through the use of a single lever.

The auto-quality control allows system performance to be tracked and trended across 32 available parameters, while the updated Summit Software permits six-way sorting into tubes and sorting into plates having as many as 1536 wells. Index-sorting logic tracks each plate-sorted cell back to its histogram or scatter plot. A touchscreen control panel facilitates daily set-up with operations designed around core laboratory workflow.

"The range of features incorporated on MoFlo Astrios elevates the sorting and productivity capabilities available to the researcher," said Brad Calvin, vice president and general manager of Beckman Coulter Flow Cytometry. "This instrument reflects our commitment to providing scientists with instruments that combine cutting-edge performance with workflow gains."

Biosafety features are prominent on the system. The Aerosol Evacuation System (AES) filters particles from all chambers where aerosols have the potential of being generated. A fully-sealed sort chamber housing on the redesigned R-Theta CyClone arm facilitates aerosol evacuation capabilities, which are tested to current ISAC guidelines. A custom BioSafety Level II cabinet option provides a cabinet that is tested to NSF-49 International Standards with the MoFlo Astrios inside.

About Beckman Coulter
Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. This year marks the company's 75th anniversary of advancing healthcare. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of consumable supplies (including reagent test kits), service and operating-type lease payments, represents about 80 percent of the company's 2009 revenue of $3.3 billion. For more information, visit www.beckmancoulter.com or www.beckmancoulter.com/75years.

Visit the MoFlo Astrios web page.

Click here or on the icon to collapse this window

ORANGE COUNTY, Calif. (October 8, 2010) - Beckman Coulter, Inc.'s new flow cytometry analysis software, Kaluza 1.1, processes multicolor files of up to 10 million events in real time and offers an analytical speed that is dramatically faster than the previous version and several hundred times faster than other commercially available software. With the cutting edge NVIDIA Tesla Supercomputer option (www.nvidia.com/tesla), Kaluza 1.1 sets a new standard for flow cytometry data processing speed.

Researchers investigating stem cell differentiation, cell signaling and circulating tumor cells are applying technologies such as cell sorting, high-complexity flow analysis, and imaging to gain deeper insights into the biology of cells. Kaluza 1.1 analyzes data from a variety of platforms, including MoFlo Series sorters, CyAn ADP and Gallios flow cytometry analyzers, and even systems such as the iCys and the iCyte automated imaging cytometers

This new version of Kaluza is the first software in the industry to be offered in a variety of translations. The availability of Kaluza in a choice of native language will facilitate intuitive flow cytometry analysis for users around the world. Downloadable language packs for Japanese and simplified Chinese are now available on www.kaluzasoftware.com, with more languages to follow soon.

Sharlene Wright, flow cytometry strategic marketing manager with Beckman Coulter, noted, "Researchers in the areas of regulatory T cells, NK cell subpopulations, and mesenchymal stem cells are focused on the analysis of the differentiation stage and on the function of very small subpopulations of cells. Data files of several million events or more are required for statistically significant results. Kaluza 1.1 enables researchers in these areas to run their high-content flow cytometry files in real time."

Kaluza Flow Cytometry Analysis Software version 1.1 is for research use only and is compatible with Windows XP, Windows Vista and Windows 7 (32 and 64-bit) operating systems. The software loads files that are compliant with Flow Cytometry Standards 2.0, 3.0, and 3.1 and is offered for both networked and stand-alone computers. Examples of Kaluza's unique data analysis tools can be viewed at www.kaluzasoftware.com, where a free, fully functional trial version of the software can be requested.

About Beckman Coulter
Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. This year marks the company's 75th anniversary of advancing healthcare. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of consumable supplies (including reagent test kits), service and operating-type lease payments, represents about 80 percent of the company's 2009 revenue of $3.3 billion. For more information, visit www.beckmancoulter.com or www.beckmancoulter.com/75years.

Visit the Kaluza web page.

Click here or on the icon to collapse this window

BREA, Calif. (October 1, 2010) - Beckman Coulter, Inc., has entered into a strategic alliance with Trillium Diagnostics LLC, under the terms of which Beckman Coulter will market specific products in North America and South America, and in the majority of Europe, Asia and Australasia.

Trillium Diagnostics products covered in this agreement include unique assays for feto-maternal hemorrhage testing (FETALtrol control) and cellular HbF level quantitation (FMH QuikQuant), as well as Leuko64, which is used for sepsis and infection detection by flow cytometry.*

Adding these products to the Beckman Coulter line for flow cytometry will enable the company to provide diagnostic laboratories and research institutes with targeted flow cytometry products that address specific unmet medical needs.

"Trillium Diagnostics has been developing high quality flow cytometry products that address unmet medical needs across the globe for over 10 years," said Bruce Davis MD, president and founder of Trillium Diagnostics. "We are confident that Beckman Coulter's broad market reach, installed flow cytometer base in clinical diagnostic laboratories, and extensive flow product portfolio, coupled with our innovative flow cytometry products, will further advance the field of cellular analysis and be of mutual benefit to patients, laboratorians and both companies."

Trillium Diagnostics will continue to work with IQ Products, bv, of The Netherlands, as manufacturer and their exclusive distributor in the Benelux countries, with Beckman Coulter granted co-exclusivity in all other global markets.

About Beckman Coulter
Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. This year marks the company's 75th anniversary of advancing healthcare. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of consumable supplies (including reagent test kits), service and operating-type lease payments, represents about 80 percent of the company's 2009 revenue of $3.3 billion. For more information, visit www.beckmancoulter.com or www.beckmancoulter.com/75years.

About Trillium Diagnostics LLC.
Trillium Diagnostics LLC, based in Bangor Maine, develops, manufactures and markets niche flow cytometry products that address unmet medical needs. Based on a foundation of recognized expertise in laboratory hematology and flow cytometry, Trillium Diagnostics is dedicated to improving healthcare outcomes by providing niche flow cytometry products that are innovative, robust and reliable. For more information visit www.trilliumdx.com.

*FETALtrol, FMH QuikQuant and Leuko64 are registered trademarks of Trillium Diagnostics. Currently FMH QuikQuant and Leuko64 are marketed as RUO in the U.S. and have not yet been cleared as an IVD by the U.S. FDA.

Click here or on the icon to collapse this window

BREA, Calif. (September 29, 2010) - Beckman Coulter, Inc. continues its tradition of displaying current and upcoming laboratory solutions at the World Stem Cell Summit, which is being held at the Marriott Renaissance Center in Detroit, Mich., October 4-6. Visitors to Booth 24 will see the latest in analyzers and services designed to optimize productivity and workflow efficiency.

Broad cellular analysis and regenerative medicine portfolios will allow Beckman Coulter to feature more ways to streamline lab performance than ever, with an emphasis on complete laboratory solutions. Featured new and upcoming products will include:
• The Quantum Cell Expansion System, a closed, automated system for cell expansion.
• The GenomeLab GeXP Genetic Analysis System.
• The Multisizer 4 particle sizing and counting system.
• Kaluza software for multiparametric analysis in flow cytometry.
• The Gallios multicolor flow cytometer displaying Kaluza software v1.1.
• The CompuCyte iCys Research Imaging System with iGeneration software.

"Beckman Coulter's experience and current product portfolio are focused on solutions that help to standardize and optimize bioprocess methods and applications in order to reduce analysis time, improve quality and enhance the overall performance of the laboratory," said Brad Calvin, vice president and general manager, Flow Cytometry Business Center at Beckman Coulter. "Our expanded portfolio offers complete and comprehensive solutions for today's cellular therapy research workflows."

Three "Luncheon with the Experts" sessions hosted by Beckman Coulter will provide attendees with the opportunity to learn how they may benefit from the analytical and workflow capabilities of the new systems. Defining Pluripotency with Multiplex Gene Expression will focus on the utilization of gene expression profiles to effectively characterize and define fully reprogrammed human iPSCs derived from somatic cells.  Optimizing, Automating and Standardizing Cell Therapy Research Workflows offers attendees strategies for standardization and enhanced optimization of bioprocessing and analysis techniques.  Characterizing Embryoid Bodies with the Coulter Principle will cover key features of the Coulter Principle and best practices for its use with stem cells, along with a brief review of recent publications implementing the Coulter Principle for characterizing embryoid bodies.

As a proud sponsor of the 2010 World Stem Cell Summit, Beckman Coulter is offering $100 discount registration passes to our partners and customers who are attending the event. For complete details on all of Beckman Coulter's products, workshops, posters and activities at this year's event, visit www.coulterflow.com/worldstemcellreport.html.

About Beckman Coulter
Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. This year marks the company's 75th anniversary of advancing healthcare. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of consumable supplies (including reagent test kits), service and operating-type lease payments, represents about 80 percent of the company's 2009 revenue of $3.3 billion. For more information, visit www.beckmancoulter.com or www.beckmancoulter.com/75years.

Click here or on the icon to collapse this window

BREA, Calif. (September 16, 2010) - Beckman Coulter, Inc. introduces Krome Orange, a novel violet-excited organic dye that expands the range of available choices and dye sensitivity limits for violet lasers. Common gating markers can be easily transferred to this fluorochrome, freeing other channels for use with more esoteric markers and enabling more versatile 10-color flow cytometry applications.

Krome Orange has excitation and emission maxima of 398 nm and 528 nm respectively and provides a brighter signal than Pacific Orange* conjugates with equivalent spectral overlaps into adjacent channels. The new dye is at least as bright as V500 and can provide more than twice the population separation obtained with Pacific Orange dye conjugates, with little compensation compared to Pacific Blue* dye.

Krome Orange conjugates show optimal performance with violet laser excitation and a 550/40 bandpass filter (the standard FL10 channel on flow cytometry systems), while no excitation is detected using a 488 nm laser. The initial release of Krome Orange includes conjugates to human CD45 and CD4, with the range of human and mouse targets to expand going forward.

"Krome Orange provides scientists with the ability to increase sensitivity for low fluorescence signals and to expand their flexibility for multi-color flow cytometry experiments," said Brad Calvin, vice president and general manager of the Beckman Coulter Flow Cytometry Business Center. "The development of this new dye underscores Beckman Coulter's commitment to expand multi-color cellular analysis technologies."

About Beckman Coulter
Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. This year marks the company's 75th anniversary of advancing healthcare. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of consumable supplies (including reagent test kits), service and operating-type lease payments, represents about 80 percent of the company's 2009 revenue of $3.3 billion. For more information, visit www.beckmancoulter.com or www.beckmancoulter.com/75years.

Click here or on the icon to collapse this window

ORANGE COUNTY, Calif. (May 11, 2010) - The Cell Lab Signaling Cytometry (Cell Lab SC) line of reagents from Beckman Coulter, Inc., offers a comprehensive set of antibodies for the detection of the phosphorylation state of signaling proteins in cells via flow cytometry.  Performing cell signaling experiments via flow enables the user to generate precise, specific and quantitative measurements of the signaling response in individual cellular subpopulations. 

The reagents, which in the initial offering are conjugated to either Alexa Fluor* 488 or Alexa Fluor 647, are released in conjunction with a new method that allows analysis of samples in whole blood. Analyzing samples in whole blood minimizes artifacts and variability introduced through sample manipulation and helps preserve the native biology of the cell. The method has also shown excellent performance when used with bone marrow, cell culture, and purified cell populations.

Antibodies in the Cell Lab SC line can be used in combination with extracellular markers to study signaling patterns in specific cellular subpopulations. Products are available for the study of apoptosis, chromatin regulation, cytoskeletal signaling, DNA damage, lymphocyte signaling, MAP kinase signaling, protein folding, translation control and other phosphorylation events.

"Using flow cytometry to get quantitative, cell-type specific data enables researchers to interrogate signaling pathways in ways previously unattainable by Western blotting," said Brad Calvin, vice president of Beckman Coulter's Flow Cytometry Business Center. "The combined whole-blood application, which incorporates robust cell preparation and high affinity antibodies, creates the potential to transform our understanding of cell signaling's role in disease, while also providing the pharmaceutical industry with the potential for improved characterization of target compound function and effect."

About Beckman Coulter
Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. This year marks the company's 75th anniversary of advancing healthcare. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of consumable supplies (including reagent test kits), service and operating-type lease payments, represents about 80 percent of the company's 2009 revenue of $3.3 billion. For more information, visit www.beckmancoulter.com.

Click here or on the icon to collapse this window

Orange County, Calif. (April 29, 2010) - Beckman Coulter, Inc. introduces Solastra, a comprehensive CE-marked panel of conjugated-antibody cocktails for the characterization of hematolymphoid neoplasia by flow cytometry. The pre-mixed and ready-to-use panels target the appropriate markers as recommended by the 2006 Bethesda International Consensus and are compatible with the WHO Classification of Tumors of Hæmatopoietic and Lymphoid Tissues (2008 revised).

The panels allow for the identification and enumeration of a comprehensive combination of markers and offer full regulatory compliance*. They can be used as an aid in the investigation of patients with abnormal hematology in order to provide data critical in the diagnosis, staging and prognosis of hematolymphoid neoplasia. Twenty-three markers are combined in seven tubes -- two tubes in the B-cell lineage kit, two tubes in the T-cell lineage kit, and three tubes in the myelomonocytic lineage kit -- each tube containing up to five relevant antibodies. Kits can be run individually or jointly and the preparation procedure is designed to offer standardization, consistency and simplicity.

The Solastra panels will streamline testing in the laboratory. Joanne Luider, (BSC ART MLT, Calgary Laboratory Services, Alberta, Canada) calculates the number of pipetting steps is reduced by up to 55 percent versus home-brew with single-color reagents: "The pre-mixed formulation minimizes preparation time, which for a busy lab like ours, saves over half a day a week on cocktail preparation," said Luider. "In addition, being ready-to-use reduces the probability of pipetting errors."

Patients will benefit from the highly sensitive and accurate testing the kits provide. "The launch of our Solastra antibody cocktails for hematolymphoid neoplasia analysis represents a significant step forward in simplification and standardization in this field," said Brad Calvin, vice president of Beckman Coulter's Flow Cytometry Business Center. "By following international consensus, developing pre-mixed cocktails and validating them in multi-site trials, we have reduced the burden and improved the reliability for performing these tests."

In addition to CD45, which is included in all seven tubes, the markers represented in the B-cell lineage kit are CD5, CD10, CD19, CD20, CD38, Kappa and Lambda. Tubes in the T-cell lineage kit offer CD2, CD3, CD4, CD5, CD7, CD8 and CD56. The myelomonocytic lineage kit tubes contain CD7, CD11b, CD13, CD14, CD15, CD16, CD33, CD34, CD56, CD117 and HLA-DR. Each antibody is conjugated to one of five dyes: FITC, PE, ECD (PE-Texas Red**), PC5.5 (PE-Cyanine 5.5) and PC7 (PE-Cyanine 7). Proprietary tandem dye technology allows Beckman Coulter to produce conjugates that are stable, bright and consistent from lot-to-lot.

About Beckman Coulter
Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of consumable supplies (including reagent test kits), service and operating-type lease payments, represent about 80 percent of the company's 2009 revenue of $3.3 billion. For more information, visit www.beckmancoulter.com.

*Per the requirements of the European In Vitro Diagnostics Directive (98/79/EC). Not available in the U.S., pending submission and clearance by the U.S. FDA. Beckman Coulter and the stylized logo are registered trademarks of Beckman Coulter, Inc. **Texas-Red is a trademark of Molecular Probes, Inc.

Click here or on the icon to collapse this window

Brea, Calif. - (March 24, 2010) - CoulterFlow.com, a feature-rich online environment for flow cytometrists, offers a variety of functions that help researchers design experiments, compare and identify appropriate reagents and simplify purchasing. New downloadable tools allow scientists to assemble best-in-class antibody panels, link to a customized My Lab page and order from an extensive online catalog. 

My Lab, a personalized workspace, allows storage, review and tracking of experiments, and access to previously ordered products.  Users can create folders and product lists, and add notes to stored experiments and links to references.

An Antibody Panel Creator helps researchers determine the best reagents and fluorochromes for a particular sample, facilitating reliable test results. Once the reagents and an optical filter are identified, the completed panel and its components can be stored in a My Lab tab or sent to the shopping cart.

Additional features include a Multi-color Reagent Selector that assists in the selection of antibodies and conjugates, allows review of the selection and works in conjunction with the researcher's My Lab page.

Experiment Design and Spectra Viewer tools can be downloaded to allow users to design experiments, select markers, choose reagents and check the spectral compatibility for the many fluorophores offered by Beckman Coulter. Data can easily be printed or converted to a PDF for reports.

"Working closely with scientists allows us to successfully address their needs in today's complex research environment," said Brad Calvin, vice president and general manager for Beckman Coulter Flow Cytometry. "The CoulterFlow.com tools provide a valuable resource for flow cytometrists and demonstrate our commitment to helping researchers achieve high-quality results."

About Beckman Coulter
Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of supplies, test kits and operating-type lease payments, represents approximately 78 percent of the company's 2008 annual revenue of $3.1 billion. For more information, visit www.beckmancoulter.com.

Click here or on the icon to collapse this window

BREA, Calif. (January 19, 2010) - Beckman Coulter, Inc. now offers Streptamer technology, providing a novel method for the isolation and characterization of functional antigen-specific T-cells by fluorescence-activated or magnet-assisted cell sorting. Streptamer technology, manufactured by IBA GmbH, includes Ag-specific multimers available in a number of human alleles and mouse models and attached to either magnetic beads or fluorescently labeled Strep-Tactin.*

The addition of the Streptamer technology to Beckman Coulter´s iTAg* MHC Tetramer and iTopia™ Immune Monitoring product lines provides researchers with a comprehensive range of methods for sorting and characterizing cells. Combined with current Tetramer and iTopia reagents, Streptamer technology allows researchers to expand their use of tetramers to include in vivo experimentation.

The reversible, antigen-specific staining of T-cells enabled by Streptamers leaves the isolated T-cells phenotypically and functionally indistinguishable from untreated cells. The technology has the potential to advance basic T-cell research as an essential prerequisite for novel immunological medicines.

"Streptamer technologies expand the range of tools available for immunologists," said Brad Calvin, vice president of Beckman Coulter's Flow Cytometry Business Center. "The reversible binding capability of the Streptamer technology allows researchers to sort and study cells in their natural state, which is not always possible with conventional antibody staining techniques. This provides for unique research applications and the ability to use targeted cells in their native condition."

The partnership with IBA GmbH provides Beckman Coulter with exclusive distribution rights for the Streptamer technology in North America and co-exclusive distribution rights for the IBA Streptamer technology outside of North America. IBA will continue direct sales and support of the Streptamer technology outside of North America.

"Beckman Coulter has an extensive global footprint for both sales and support, which will allow our Streptamer products to reach a large and diverse customer set," said Lothar Germeroth, CEO of IBA. "With this relationship, we believe that IBA will continue to advance and expand the use of its Streptamer reagents to address the urgent need of modern drug discovery and life science research for the isolation of functional cells that provide novel insights into the biology of the immune system."

About Beckman Coulter
Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of supplies, test kits and operating-type lease payments, represents approximately 78 percent of the company's 2008 annual revenue of $3.1 billion. For more information, visit www.beckmancoulter.com.

About IBA GmbH
IBA GmbH, located in Goettingen, Germany, is dedicated to providing high quality tools for life science research. Being the "Tag-company" IBA covers, with its TAGnologies, the entire production of recombinant proteins. As competent partner for the life science industry and academia, IBA is one of the foremost providers of tag-derived products and services for PCR, cloning (StarGate* technology), transfection (MATra technology), protein expression and purification, detection (Strep-tag* technology), immobilization, and cell isolation. IBA´s proprietary Streptamer technology enables the detection and isolation of functional antigen-specific lymphocytes with reversible staining reagents. IBA has created a range of different Streptamer products enabling the functional characterization of immune cells. For more information, visit www.iba-go.com.

Click here or on the icon to collapse this window

Orange County, Calif. (December 11, 2009) - Beckman Coulter, Inc. and CompuCyte Corporation have entered into a five-year global distribution agreement, under the terms of which Beckman Coulter will have the right to distribute CompuCyte laser scanning cytometers in cellular analysis markets worldwide. Beckman Coulter will maintain exclusive distribution rights for CompuCyte iGeneration technology outside of North America, and will share with CompuCyte the right to sell the instrumentation to research institutions and pharmaceutical companies within the U.S., Canada and Mexico. CompuCyte will continue worldwide direct sales of LSC instrumentation for automated tissue analysis.

"This agreement provides us with a sophisticated imaging platform that nicely complements our growing flow cytometry product portfolio," stated Brad Calvin, Beckman Coulter vice president for flow cytometry. "The iGeneration line of imaging cytometers will be an important addition to the range of products we are launching. This will enable us to provide researchers around the world with a broad range of technology for cell-based research from a single service provider, while further demonstrating our commitment to the research market."

Dr. Elena Holden, CompuCyte president and CEO, welcomed the new agreement: "Our distribution alliance is built on a great synergy between the two companies. Beckman Coulter is a renowned leader in flow cytometry instrumentation and CompuCyte is recognized as the first company to introduce solid-phase imaging cytometry technology (LSC) to the marketplace. LSC technology is complementary to flow cytometry and applies similar analysis principles to adherent cellular and tissue specimens, combining the resulting analytic data with high-quality imaging. The agreement with Beckman Coulter furthers CompuCyte´s commitment to the growing quantitative imaging cytometry market by enlarging the LSC technology distribution channel, and by bringing outstanding technical support to our customers worldwide."

About Beckman Coulter
Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of supplies, test kits and operating-type lease payments, represents approximately 78 percent of the company's 2008 annual revenue of $3.1 billion. For more information, visit www.beckmancoulter.com.

About CompuCyte Corp.
CompuCyte Corporation, a privately held corporation headquartered in Westwood, Massachusetts, is a pioneer in the field of quantitative imaging cytometry (QIC). The company´s comprehensive line of laser scanning cytometry instrumentation is applied to automated cellular and tissue analysis in life science research, drug safety, toxicology studies and clinical trials. Committed to educational programs and promotion of the science and practice of LSC technology, CompuCyte actively maintains the International QIC Centers of Excellence program (www.imagingcytometrycenter.com) and the annual International QIC Symposium. More information about CompuCyte Corporation and its technology may be found at www.compucyte.com.

Click here or on the icon to collapse this window

Orange County, Calif. (November 17, 2009) - Beckman Coulter Inc. announces the introduction of its Kaluza Flow Cytometry Analysis Software, a package that greatly reduces processing and analysis times, allowing researchers more time to explore their data. Kaluza Software features new tools that simplify the management of multiple complex data sets, allows visualization of high-content data in different spatial dimensions on a single plot, and provides real-time analysis of high-content flow cytometry files.

A dynamic workspace facilitates automatic organization of plots, which combines with a zoom in/zoom out feature to provide an intuitive environment for data exploration. Auto-Layout intelligently reconfigures the workspace and minimizes the clicks required to create and maintain an analysis.

Data replay is made quick and easy with automatic loading of the original plots, gates, and colors from files with embedded analysis protocols. A radial menu provides fast access to all plot and region editing features.

Tree plots easily represent data that typically requires dozens of plots, gates and regions. Each phenotype can be used as a gate for further data exploration. Radar plots provide a multi-dimensional view of data without drawing a single gate. These plots reveal relevant and rare populations that are typically not seen using traditional bi-variate plots and gating strategies.

Sharlene Wright, flow cytometry strategic marketing manager with Beckman Coulter, noted, "Cytometrists can spend hours, days and even weeks formatting data to get the right information and presentation. With Kaluza Software, this can now be done in minutes, giving researchers the opportunity to spend more time in discovery and to get more information from their data."

Kaluza Flow Cytometry Analysis Software will readily scale to meet the expanding requirements of future instrumentation. Patented technology enables remarkably fast refresh rates for even large, complex data sets. The package works with the majority of FCS-compliant files and with most cytometers. It can be used with both network and stand-alone computers and is offered for research use only. Functional examples of Kaluza data analysis can be viewed at www.kaluzasoftware.com, where a free, fully functional trial version of the software is available.

About Beckman Coulter
Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of supplies, test kits and operating-type lease payments, represents approximately 78 percent of the company's 2008 annual revenue of $3.1 billion. For more information, visit www.beckmancoulter.com.

Beckman Coulter and the stylized logo are registered trademarks of Beckman Coulter, Inc. Kaluza is a trademark of Beckman Coulter, Inc

Click here or on the icon to collapse this window

ORANGE COUNTY, Calif. (September 3, 2009) - Beckman Coulter, Inc. and Propel Labs, LLC., have entered into a new strategic alliance for flow cytometry. As part of this alliance, Propel will support Beckman Coulter with field upgrades of MoFlo instruments to the specifications associated with the more recent XDP version.

"Customers that have MoFlo systems are extremely loyal to the product and have been for many years," said Brad Calvin, vice president of Beckman Coulter's Flow Cytometry Business Center. "This alliance demonstrates our continued support for these customers and a product that has become central to their research applications."

"We're very pleased to provide the XDP upgrade to MoFlo customers and to be aligned with Beckman Coulter, said Matt Ottenberg, CEO and founder of Propel Labs. "This reinforces the vision of a modular, scalable and upgradeable MoFlo platform."

About Beckman Coulter
Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of supplies, test kits and operating-type lease payments, represents approximately 78 percent of the company's 2008 annual revenue of $3.1 billion. For more information, visit www.beckmancoulter.com.

About Propel Labs
Propel Labs, LLC, based in Fort Collins, Colorado is a privately held bio-instrumentation development company with in-depth expertise in flow cytometry. Propel Labs delivers rapid time to market bio-instrumentation systems to ensure maximum return on investment for our customers. For more information, visit www.propel-labs.com.

Beckman Coulter and the stylized logo are registered trademarks of Beckman Coulter, Inc. MoFlo is a trademark of Beckman Coulter, Inc.

Click here or on the icon to collapse this window

Fullerton, Calif. (March 9, 2009) - Beckman Coulter, Inc. introduces the Gallios Flow Cytometry system, an instrument that delivers analytical excellence, coupling extraordinary sensitivity, resolution and dynamic range with high-speed data collection. The instrument's unprecedented detection capabilities and easy-to-use software, combined with new dyes -- some with proprietary tandem dye technology -- facilitates superior performance of multi-color flow cytometry assays.

Developed for the research and biopharmaceutical markets, with input from a number of investigators, the multi-color, multi-laser Gallios is the first in a series of key flow cytometry instrument, software and reagent releases that Beckman Coulter plans to announce this year.

A particular emphasis on optical and electronics design, combined with powerful automation and software tools, allows Gallios to greatly enhance the efficiency and analytical capabilities of flow cytometry laboratories. Patented electronics provide accurate and efficient digital signal processing at high event rates over a wide dynamic range of fluorescence intensities. These benefits are packaged in a compact analyzer that delivers stable performance over long periods of time and across a wide range of operating temperatures.

The Gallios houses up to three highly reliable, solid-state lasers in standard red and blue, with violet available as an option. Easily interchanged optical filters facilitate detection of a variety of dyes and wavelengths.

An innovative forward-scatter detector provides up to three measurements of cell size and visualization of particles down to 0.404µm in diameter. A side-scatter detector incorporates an independently focused, high-performance photodiode with electronic attenuation. Six fluorescence detectors provide simultaneous acquisition of up to six fluorescence signals. Up to four fluorescence detectors can be added to the system, enabling concurrent reading of up to 10 colors. Simultaneous measurements of integral, peak and width are available for all parameters, including scatter and fluorescence signals. A selection of up to 62 parameters can be processed per analysis, at acquisition rates of 25,000 events-per-second, with high yield. Three scaleable configurations allow for the future addition of more lasers and fluorescence detectors as the applications for complex multi-color flow cytometry expand.

According to Brad Calvin, vice president of Beckman Coulter's Flow Cytometry Business Center, "Every aspect of Gallios' optics design increases application performance, sensitivity and resolution. Our systems have the potential to enhance flow laboratory efficiency by increasing productivity and improving the reliability and reproducibility of results, thus reducing the cost of flow cytometry testing."

Beckman Coulter is also launching www.coulterflow.com -- a web portal that will enrich cytometry research. Features of this resource include a variety of specially designed interactive tools, such as cell signaling maps, a fluorochrome spectral overlap viewer and an experimental design tool to help cytometrists set up applications. Users will be able to access the latest flow cytometry product information, view extensive reference resources and order reagents.

About Beckman Coulter
Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of supplies, test kits and operating-type lease payments, represents approximately 78 percent of the company's 2008 annual revenue of $3.1 billion. For more information, visit www.beckmancoulter.com.

*For research use only. Not for use in diagnostic procedures. Product in development.

Click here or on the icon to collapse this window